Additionally, phase I trials found combinations of HCQ with temozolomide [1467] or the mTOR inhibitor temsirolimus [1468] to be safe and show beneficial antitumor activity in solid tumors including CRC. This evidence concerns the gene MTOR and colorectal carcinoma.